{"id":"W3168444608","doi":"10.1200/jco.2021.39.15_suppl.4520","title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Avelumab; Metastatic Urothelial Carcinoma; Carboplatin; Gemcitabine; Internal medicine; Oncology; Bladder cancer; Clinical endpoint; Cystectomy; Chemotherapy; Cisplatin; Clinical trial; Pembrolizumab; Cancer; Urothelial carcinoma; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003495228,0.0006891247,0.001446879,0.0002920882,0.0003066316,0.0009921688,0.0005980865,0.0006833874,0.002053017],"category_scores_gemma":[0.001940165,0.0003190919,0.002386838,0.0004902493,0.0005633149,0.0006020783,0.0005817672,0.001245759,0.0002696439],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005775388,"about_ca_system_score_gemma":0.0006883046,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005156922,"about_ca_topic_score_gemma":0.002128988,"domain_scores_codex":[0.9987341,0.0008251763,0.00006575279,0.0001953409,0.00008457959,0.00009513985],"domain_scores_gemma":[0.9987707,0.0003305848,0.0003562515,0.0001781863,0.00004561859,0.0003186795],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8144092,0.005321776,0.09526409,0.001434805,0.01351111,0.000151788,0.0002766739,0.002224387,0.01538317,0.0002208644,0.003199848,0.04860221],"study_design_scores_gemma":[0.372099,0.1622321,0.4205084,0.0002768069,0.02454096,0.0009389737,0.0003668627,0.005507824,0.004620777,0.001191071,0.007570795,0.0001464413],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941299,0.003167794,0.0002833052,0.0001945391,0.00003518667,0.000297855,0.001276192,0.00002529031,0.0005899398],"genre_scores_gemma":[0.9946009,0.0006415809,0.0004959425,0.0002761697,0.00004435439,0.0004025621,0.003128027,0.00001234056,0.000398091],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003495228,"threshold_uncertainty_score":0.01848477,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1318837984652909,"score_gpt":0.4518760411246524,"score_spread":0.3199922426593615,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}